Roche dumps another partnered asset.

Meanwhile, Ichnos Glenmark takes a different trispecific multiple myeloma approach.

BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.

Imdelltra seems headed for full approval, raising questions about Zai’s accelerated plan.

Evopoint reveals intriguing but opaque first-in-human data for XNW27011.

Bristol buys into the frenzy, and VEGF bispecific value inflation continues.

LY4170156 looks similar to Genmab’s rina-S, but cost Lilly a lot less.